Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 93 of 6351
-
Precision radiation may cure prostate cancer with fewer side effects
Cure Recruiting nowThe purpose of this prostate cancer research study is to investigate: 1. For early-stage patients, the use of a single session of high dose stereotactic body radiotherapy (SBRT) delivered to the tumor within the prostate, not to the entire prostate, as curative treatment of pros…
Phase 2 • Sponsor: University of Miami • Aim: Cure
Last updated Jun 27, 2026 09:06 UTC
-
New obesity drug retatrutide takes on tirzepatide in major trial
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can whole blood save more kids? major trial launches
Disease control Recruiting nowThe MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blo…
Phase 3 • Sponsor: Philip Spinella • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Triple attack: radiation, immunotherapy, and chemo take on tough breast cancer
Disease control Recruiting nowTriple-negative breast cancer (TNBC) presents significant challenges due to its limited treatment options and poor efficacy. While neoadjuvant chemotherapy has improved breast-conserving rates and extended survival for TNBC patients, this subtype still faces issues such as restri…
Phase 3 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for lung cancer patients who can't use standard immunotherapy alone
Disease control OngoingThe study aims to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with PD-L1 negative.
Phase 3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
One-Time cell therapy aims to tame tough scleroderma
Disease control OngoingThe purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Triple threat: new combo aims to outsmart advanced liver cancer
Disease control Recruiting nowTHis study aims to evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab or Atezolizumab combined with Bevacizumab for the first-line treatment of advanced HCC.
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could this drug stop the body from turning muscle into bone?
Disease control OngoingThis study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP. The study is looking a…
Phase 2/3 • Sponsor: Ashibio Inc • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could this injection delay Alzheimer's decline?
Disease control OngoingThe purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including sc…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New pneumonia vaccine trial aims to shield 3,000 kids from deadly infection
Vaccine Recruiting nowA Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogen…
Phase 3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
-
Postpartum blood pressure control may stop preeclampsia from leading to lifelong hypertension
Prevention Recruiting nowThe long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lif…
Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Jul 22, 2026 00:00 UTC
-
Immunotherapy shows promise for untreated rectal cancer in chinese patients
Disease control OngoingThe main goal of this study is to evaluate the effect of dostarlimab monotherapy in Chinese participants with locally advanced Mismatch-repair deficient (dMMR)/ Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment.
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Groundbreaking gene therapy aims to fix immune system in rare disease
Disease control By invitation onlyThis is an open-label, single-arm, multicenter Phase 1/2 study evaluating the safety and efficacy of gene therapy by transplantation of Prime Edited autologous CD34+ stem cells modified ex vivo (PM359) in participants with autosomal recessive Chronic Granulomatous Disease (CGD) c…
Phase 1/2 • Sponsor: Prime Medicine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThe goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Systemic lupus erythematosus (SLE).
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New catheter aims to treat dangerous blood clots in the lungs without ICU stay
Disease control Recruiting nowTo demonstrate the efficacy and safety of the 8F BASHIR™ .035 Endovascular Catheter and the 8F BASHIR™ S-B .035 Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse sprays of r-tPA into the pulmonary arteries for the treatment …
Sponsor: Thrombolex, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Engineered immune cells take on childhood blood cancers in early trial
Disease control Recruiting nowThe study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse).…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for pancreatic cancer: targeted drug enters final testing phase
Disease control OngoingThe purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Can we catch type 1 diabetes before it strikes?
Prevention By invitation onlyThe aim is to investigate whether screening for islet autoantibodies, regular follow-up, and increased knowledge in families about the progression of the disease in children at high genetic risk or with single or multiple islet autoantibodies (stage 1 or 2 type 1 diabetes) ensure…
Sponsor: Lund University • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
Simple blood test could spot multiple cancers early
Diagnosis Recruiting nowThis is a prospective, multi-center clinical study of Multi-Cancer Early Detection (MCED) testing in cancer patients and healthy volunteers. This study was designed to establish a clinical and molecular database using circulating DNA from both cancer patients and non-cancer parti…
Sponsor: Chang Gon Kim • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
New weekly shot could reverse liver damage in MASH patients
Disease control Recruiting nowThis study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute …
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC